Compare TBPH & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | QURE |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.9M | 1.1B |
| IPO Year | 2013 | 2013 |
| Metric | TBPH | QURE |
|---|---|---|
| Price | $16.87 | $44.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | $18.40 | ★ $45.00 |
| AVG Volume (30 Days) | 576.4K | ★ 1.5M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,386,000.00 | $13,107,000.00 |
| Revenue This Year | $8.46 | $126.12 |
| Revenue Next Year | N/A | $200.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.99 | $8.73 |
| 52 Week High | $21.03 | $71.50 |
| Indicator | TBPH | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 61.29 |
| Support Level | $16.80 | $39.50 |
| Resistance Level | $17.17 | $50.47 |
| Average True Range (ATR) | 0.06 | 2.20 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 33.33 | 90.05 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.